Jade Biosciences (JBIO) news
Recent news
Jade Biosciences, Inc Q2 basic EPS USD -0.76
AInvest Wire · Aug 10, 2026Jade Biosciences - Paragon barred from new campaigns targeting licensed target for at least five years - SEC filing
AInvest Wire · Jul 1, 2026Jade Biosciences - to pay Paragon low to mid-single-digit percentage royalties on net sales of licensed products - SEC filing
Jade Biosciences, Inc. has entered into a series of agreements with Paragon, including the Paragon Option Agreement and the JADE-001 License Agreement, under which it has secured exclusive rights to develop and commercialize antibody-based therapies targeting the APRIL protein. As part of these…
AInvest Wire · Jul 1, 2026Jade Biosciences - to pay up to $22 mln in milestone payments to Paragon - SEC filing
AInvest Wire · Jul 1, 2026Jade Biosciences - enters exclusive worldwide license agreement with Paragon Therapeutics - SEC filing
Jade Biosciences recently announced a significant development in its partnership with Paragon Therapeutics, entering into an exclusive worldwide license agreement for key assets that form the foundation of its therapeutic pipeline. This agreement builds on the company’s history as the fourth…
AInvest Wire · Jul 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.